TITLE

Gentium Voluntarily Pulls NDA For Defibrotide; Shares Tumble

PUB. DATE
August 2011
SOURCE
Bioworld Week;8/22/2011, Vol. 19 Issue 33, p5
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the decline in August 2011 shares of Gentium SpA in the aftermath of its announcement on its voluntary withdrawal of the new drug application (NDA) for defibrotide in 2011 in the U.S.
ACCESSION #
65236294

 

Related Articles

  • Clinic Roundup.  // BioWorld Today;11/13/2013, Vol. 24 Issue 219, p11 

    This section offers news briefs on clinical drug trials of several pharmaceutical companies, as of November 13, 2013. It announces the completion of the Phase I clinical trial conducted by Gentium SpA which evaluated the effect of defibrotide on the coagulation and fibrinolytic systems in vivo....

  • Gentium Voluntarily Pulls NDA For Defibrotide; Shares Tumble. Powers, Marie // BioWorld Today;8/19/2011, Vol. 22 Issue 161, p1 

    This article reports on the voluntary withdrawal by Gentium SpA of its new drug application (NDA) for defibrotide. The company took the move 36 hours after receiving a letter from the Food and Drug Administration ( FDA) which cited a number of issues regarding the NDA for defibrotide. The drug...

  • Other News To Note.  // BioWorld Today;11/15/2013, Vol. 24 Issue 221, p2 

    The article presents global biopharmaceutical industry news briefs as of November 15, 2013. Aduro Biotech Inc. presented preclinical data demonstrating antitumor activity by the company's synthetic derivatives of natural peptides. Gentium SpA said that defibrotide has been designated as an...

  • GENTIUM COMPLETES PRECLINICAL/CLINICAL DEFIBROTIDE STUDIES.  // Worldwide Biotech;Mar2011, Vol. 23 Issue 3, p1 

    The article provides information on a drug developed by Gentium S.p.A. in Italy, called defibrotide, for the prevention and treatment of veno-occlusive disease (VOD), a life threatening condition of the liver that occur when a patient undergoes stem cell transplant. A detailed description of VOD...

  • PIPELINE.  // Nurse Practitioners Prescribing Reference;Fall2010, Vol. 17 Issue 3, pA20 

    The article offers clinical trial phase updates of various drugs such as prednisone from Horizon Pharmaceutical Corp. to treat musculoskeletal disorders and octreolin from Chiasma Inc. to treat acromegaly.

  • The European Medicines Evaluation Agency. Bosanquet, Nick // BMJ: British Medical Journal (International Edition);2/12/94, Vol. 308 Issue 6926, p430 

    Focuses on the impact of the establishment of the 'European Medicines Evaluation Agency' (EMEA) on drug innovation in Europe. Centralization of community licensing of biotechnology and innovatory drugs; Recognition of licenses from member states with binding arbitration; Benefits of EMEA for...

  • New Drugs in the Pipeline.  // CenterWatch Monthly;Dec2016, Vol. 23 Issue 12, p16 

    A list of the drugs added to the Drugs in Clinical Trials Database of clinical trials information publication "CenterWatch" in November 2016 is presented including ZYN001 from pharmaceutical company Zynerba, ATI-50001 from Aclaris Therapeutics, and WBP3155 from CStone Pharma.

  • WEEK IN REVIEW.  // BioWorld Insight;1/24/2011, Vol. 19 Issue 4, p5 

    The article offers news briefs in the U.S. related to the drug development industry which include the 7.1 million U.S. dollar increase in public offering at Ardea Biosciences Inc., the acquisition of Amgen Inc.'s manufacturing facility in Fremont, California by Boehringer Ingelheim GmbH, the...

  • WORD ON THE STREET.  // BioWorld Insight;1/24/2011, Vol. 19 Issue 4, p5 

    The article presents quotes from Kleanthis Xanthopoulos, president and chief executive officer (CEO) of Regulus Therapeutics Inc., stressing the challenges facing the drug development industry, Simos Simeonidis, analyst at Rodman and Renshaw, commenting on MannKind Corp.'s inhaled insulin...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics